These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

32 related articles for article (PubMed ID: 8529957)

  • 1. Squalamines in Blockade of Tumor-Associated Angiogenesis and Cancer Progression.
    Sterling C; Márquez-Garbán D; Vadgama JV; Pietras RJ
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nature of tumour rejection antigens in ovarian cancer.
    Want MY; Lugade AA; Battaglia S; Odunsi K
    Immunology; 2018 Oct; 155(2):202-210. PubMed ID: 29772069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme.
    Jindal V
    Mol Neurobiol; 2018 Nov; 55(11):8236-8242. PubMed ID: 29524050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR-T cell therapy in ovarian cancer: from the bench to the bedside.
    Zhu X; Cai H; Zhao L; Ning L; Lang J
    Oncotarget; 2017 Sep; 8(38):64607-64621. PubMed ID: 28969098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes.
    Lanitis E; Smith JB; Dangaj D; Flingai S; Poussin M; Xu S; Czerniecki BJ; Li YF; Robbins PF; Powell DJ
    Hum Gene Ther; 2014 Aug; 25(8):730-9. PubMed ID: 25003657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.
    Reyes HD; Thiel KW; Carlson MJ; Meng X; Yang S; Stephan JM; Leslie KK
    Mol Diagn Ther; 2014 Apr; 18(2):137-51. PubMed ID: 24403167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels.
    Lanitis E; Dangaj D; Hagemann IS; Song DG; Best A; Sandaltzopoulos R; Coukos G; Powell DJ
    PLoS One; 2012; 7(11):e49829. PubMed ID: 23189165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic Steroids in Human Cancer Therapy.
    Pietras RJ; Weinberg OK
    Evid Based Complement Alternat Med; 2005 Mar; 2(1):49-57. PubMed ID: 15841278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary.
    Ross JS; Yang F; Kallakury BV; Sheehan CE; Ambros RA; Muraca PJ
    Am J Clin Pathol; 1999 Mar; 111(3):311-6. PubMed ID: 10078105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor.
    Meden H; Kuhn W
    Eur J Obstet Gynecol Reprod Biol; 1997 Feb; 71(2):173-9. PubMed ID: 9138962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and significance of HER-2/neu amplification in epithelial ovarian cancer.
    Wong YF; Cheung TH; Lam SK; Lu HJ; Zhuang YL; Chan MY; Chung TK
    Gynecol Obstet Invest; 1995; 40(3):209-12. PubMed ID: 8529957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER-2/neu gene amplification in cervical cancer in Chinese women of Hong Kong and China.
    Wong YF; Chung TK; Cheung TH; Lam SK; Tam OS; Lu HJ; Xu FD; Chang AM
    J Obstet Gynaecol Res; 1996 Apr; 22(2):171-5. PubMed ID: 8697348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer.
    Rubin SC; Finstad CL; Federici MG; Scheiner L; Lloyd KO; Hoskins WJ
    Cancer; 1994 Mar; 73(5):1456-9. PubMed ID: 7906607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
    Afify AM; Werness BA; Mark HF
    Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.